Receptor Activator for Nuclear Factor kappa B Ligand (RANKL) as an osteoimmune key regulator in bone physiology and pathology

Acta Histochemica

Volumn 113, Issue 2, 2011, Pages 73-81

  Narducci, Paola ^a   Bareggi, Renato ^a   Nicolin, Vanessa ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Bone; Bone disease; Bone resorption; Osteoclasts; RANKL

Indexed keywords

AMGN 0007; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; UNCLASSIFIED DRUG;

BONE DISEASE; BONE METASTASIS; BONE REMODELING; BONE TURNOVER; BREAST CANCER; BREAST CARCINOMA; CANCER RADIOTHERAPY; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; HYPERCALCEMIA; IMMUNE SYSTEM; INFLAMMATORY DISEASE; MULTIPLE MYELOMA; NONHUMAN; OSSIFICATION; OSTEOARTHRITIS; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

ANIMALS; BONE AND BONES; HUMANS; OSTEOCLASTS; RANK LIGAND;

EID: 79151481586     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2009.10.003     Document Type: Review

References (84)

1. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997, 390:175-179.
2. Asagiri M, Takayanagi H The molecular understanding of osteoclast differentiation. Bone 2007, 40:251-264.
3. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001, 16:348-360.
4. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, et al. A phase I study of AMGN-0007 a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003, 97:887-892.
5. Boyle WJ, Simonet WS, Lacey DL Osteoclast differentiation and activation. Nature 2003, 423:337-342.
6. Burkiewicz JS, Scarpace SL, Bruce SP Denosumab in osteoporosis and oncology. Ann Pharmacother 2009, 43:1445-1455.
7. Burger EH, Van der Meer JW, Van de Gevel J.S, Gribnau JC, Thesingh GW, Van Furth R. In vitro formation of osteoclasts from long-term cultures of bone marrow mononuclear phagocytes. J Exp Med 1982, 156:1604-1614.
8. Buijs JT, Que I, Löwik CW, Papapoulos SE, van der Pluijm G. Inhibition of bone resorption and growth of breast cancer in the bone microenvironment. Bone 2009, 44:380-386.
9. Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ, et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 2008, 25:119-129.
10. Cross SS, Yang Z, Brown NJ, Balasubramanian SP, Evans CA, Woodward JK, et al. Osteoprotegerin (OPG) - a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis?. Int J Cancer 2006, 118:1901-1908.
11. Cheven BA, Visser JW, Nijweide PJ. In vitro osteoclast generation from different bone marrow fractions, including a highly enriched hematopoietic stem cell population. Nature 1986, 321:79-81.
12. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, et al. Denosumab rheumatoid arthritis study group: Denosumab treatment effects on structural damage, bone mineral density and bone turnover in rheumatoid arthritis. Arthritis Rheum 2008, 58:1299-1309.
13. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999, 13:2412-2424.
14. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003, 111:1221-1230.
15. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000, 103:41-50.
16. Fleisch H Bisphosphonates: mechanisms of action. Endocr Rev 1998, 19:80-100.
17. Fili S, Karalaki M, Schaller B Therapeutic implications of osteoprotegerin. Cancer Cell Int 2009, 12(9):26.
18. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000, 43:250-258.
19. Harris ED Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 1990, 322:1277-1289.
20. Higeyama Y, Pap T, Kunzler P, Simmen BR, Gay RE, Gay S Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum 2000, 43:2523-2530.
21. Hofbauer LC, Heufelder AE, Osteoprotegerin Erben RG RANK, and RANK ligand: the good, the bad, and the ugly in rheumatoid arthritis. J Rheumatol 2001, 28:685-687.
22. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999, 140:4367-4370.
23. Hofbauer LC, Rachner T, Singh SK Fatal attraction: why breast cancer cells home to bone. Breast Cancer Res 2008, 10:101.
24. Holen I, Cross SS, Neville-Webbe HL, Cross NA, Balasubramanian SP, Croucher PI, et al. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo - a role in tumour cell survival?. Breast Cancer Res Treat 2005, 92:207-215.
25. Honore P, Luger NM, Sabino MAC, Schwei MJ, Rogers SD, Mach DB, et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nature Med 2000, 6:521-528.
26. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999, 96:3540-3545.
27. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995, 10:1478-1487.
28. Ito S, Wakabayashi K, Ubukata O, Hayashi S, Okada F, Hata T. Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution. J Biol Chem 2002, 277:6631-6636.
29. Josien R, Wong BR, Li HL, Steinman RM, Choi Y, TRANCEa TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells, J Immunol 1999;162:2562-2568.
30. Juji T, Hertz M, Aoki K, Horie D, Ohya K, Gautam A, et al. A novel therapeutic vaccine approach, targeting RANKL, prevents bone destruction in bone-related disorders. J Bone Miner Metab 2002, 20:266-268.
31. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006, 440:692-696.
32. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
33. Kong Y-Y, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-309.
34. Khosla S, Melton LJ, Riggs BL. Estrogen and the male skeleton. J Clin Endocrinol Metab 2002, 87:1443-1450.
35. Kostenuik PJ, Capparelli C, Morony S, Adamu S, Shimamoto G, Shen V, Lacey DL, et al. OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology 2001, 142:4295-4304.
36. Kwan Tat S, Amiable N, Pelletier JP, Boileau C, Lajeunesse D, Duval N, et al. Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis. Rheumatology (Oxford) 2009, Sep 17.
37. Kwon BS, Wang S, Udagawa N, Haridas V, Lee ZH, Kim KK, et al. TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. FASEB J 1998, 12:845-854.
38. Lam J, Nelson CA, Ross FP, Teitelbaum SL, Fremont DH Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J Clin Invest 2001, 108:971-979.
39. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000, 97:1566-1571.
40. Locksley RM, Killeen N, Lenardo MJ The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001, 104:487-501.
41. Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A, Morony S, et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999, 13:1015-1024.
42. Mackie PS, Fisher JL, Zhou H, Choong PF Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer 2001, 84:951-958.
43. Marks SC, Walker DG The hematogenous origin of osteoclasts: experimental evidence from osteopetrotic (microphthalmic) mice treated with spleen cells from beige mouse donors. Am J Anat 1981, 161:1-10.
44. Martin TJ, Sims NA Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 2005, 11:76-81.
45. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. AMG 162 bone loss study group. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006, 354:821-883.
46. Miyazaki T, Tanaka S, Sanjay A, Baron R The role of c-Src kinase in the regulation of osteoclast function. Mod Rheumatol 2006, 16:68-74.
47. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001, 61:4432-4436.
48. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998, 253:395-400.
49. Naito A, Azuma S, Tanaka S, Miyazaki T, Takaki S, Takatsu K, et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 1999, 4:353-362.
50. Narducci P, Bareggi R, Nicolin V Interaction of human recombinant tumor necrosis factor-related apoptosis-inducing ligand and osteoprotegerin could contribute to enhancement of the erosive processes induced by human synovial cells. J Rheumatol 2009, 36:1837-1839.
51. Nicolin V, Narducci P Soluble TRAIL could enhance bone destruction acting on Rank-ligand in estrogen-independent human breast cancer cell line MDA-MB-231. Acta Histochem 2008 Epub ahead of print,. doi:10.1016/j.acthis.2008/09.011.
52. Nicolin V, Narducci P, Celeghini C Effect of recombinant TRAIL in a murine co-culture system of osteoclastogenesis. Eur J Histochem 2008, 52:75-78.
53. Nicolin V, Bortul R, Bareggi R, Baldini G, Martinelli B, Narducci P Breast adenocarcinoma MCF-7 cell line induces spontaneous osteoclastogenesis via a RANK-ligand-dependent pathway. Acta Histochem 2008, 110:388-396.
54. Pecherstorfer M. Treatment options for breast cancer and bone metastases. Womens Health (Lond Engl) 2009;5:149-63. [Review].
55. Quinn JMW, Neale S, McGee JOD, Athanasou NA Human osteoclast formation from blood monocytes, peritoneal macrophages, and bone marrow cells. Calcif Tissue Int 1998, 62:527-531.
56. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, et al. Osteoclasts are essential for TNF-mediated joint destruction. J Clin Invest 2002, 110:1419-1427.
57. Riggs BL, Khosla S, Melton LJ. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002, 23:279-302.
58. Rivollier A, Mazzorana M, Tebib J, Piperno M, Aitsiselmi T, Rabourdin-Combe C, et al. Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. Blood 2004, 104:4029-4037.
59. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000, 88:2961-2978.
60. Romas E, Sims NA, Hards DK, Lindsay M, Quinn JW, Ryan PF, et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 2002, 161:1419-1427.
61. Roodman GD Cell biology of the osteoclast. Exp Hematol 1999, 27:1229-1241.
62. Ross FP RANKing the importance of measles virus in Paget's disease. J Clin Invest 2000, 105:555-558.
63. Russell RG, Rogers MJ Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999, 25:97-106.
64. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006, 203:2673-2682.
65. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
66. Sofat N. Analysing the role of endogenous matrix molecules in the development of osteoarthritis. Int J Exp Pathol 2009, 90:463-479.
67. Southby J, Kissin MW, Danks JA, Hayman JA, Moseley JM, Henderson MA, et al. Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. Cancer Res 1990, 50:7710-7716.
68. Stolina M, Adamu S, Ominsky M, Dwyer D, Asuncion F, Geng Z, et al. RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J Bone Miner Res 2005, 20:1756-1765.
69. Suda T Modulation of osteoclast differentiation and function by the new member of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999, 20:345-357.
70. Takayanagi H. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002, 3:889-901.
71. Takayanagi H Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007, 7:292-304.
72. Tanaka S Therapeutic vaccination approach against pathological bone disease. Clin Calcium 2002, 12:932-934.
73. Tan KB, Harrop J, Reddy M, Young P, Terrett J, Emery J, Moore G, et al. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 1997, 204:35-46.
74. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004, 5:457-475.
75. Theill LE, Boyle WJ, Penninger JM RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 2002, 20:795-823.
76. Udagawa N, Takahashi N, Akatsu T, Tanaka H, Sasaki T, Nishihara T, et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci USA 1990, 87:7260-7764.
77. Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Gründker C, et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002, 29:680-686.
78. Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J, et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 2006, 24:33-63.
79. Williamson E, Bilsborough JM, Viney JL Regulation of mucosal dendritic cell function by receptor activator of NF-kappa B (RANK)/RANK ligand interactions: impact on tolerance induction. J Immunol 2002, 169:3606-3612.
80. Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997, 272:25190-25194.
81. Wong BR, Josien R, Lee SY, Vologodskaia M, Steinman RM, Choi Y The TRAF family of signal transducers mediates NF-ΚB activation by the TRANCE receptor. J Biol Chem 1998, 273:28355-28359.
82. Yasuda H Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998, 95:3597-3602.
83. Ye H, Arron JR, Lamothe B, Cirilli M, Kobayashi T, Shevde NK, et al. Distinct molecular mechanism for initiating TRAF6 signalling. Nature 2002, 25:443-447.
84. Yoneda T, Hiraga T Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 2005, 328:679-687.